Fierce Biotech
Oryon shines out of stealth with $21M to fight Parkinson’s disease
When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. The former internist-turned-biotech CEO knew a thing or two about Parkinson’s—an area Oryon is targeting with an autologous neuron replacement therapy designed to restore dopaminergic function.